收購+增資 九洲藥業(603456.SH)斥1.2億元獲康川濟醫藥51%股權
格隆匯1月3日丨九洲藥業(603456.SH)公佈,公司擬以自有資金4000萬元收購南京康川濟醫藥科技有限公司(簡稱“康川濟醫藥”或“標的公司”)25.76%股權,同時出資8000萬元對標的公司進行增資,認繳新增註冊資本113.32萬元。該次交易完成後,康川濟醫藥將成為公司的控股子公司,公司合計持有康川濟醫藥51%的股權。
康川濟醫藥成立於2013年,是一家專業的製劑研發公司,擁有先進的緩控釋、軟膠囊、口腔速溶、外用製劑、注射劑等製劑技術平台,主要從事創新藥製劑CMC研究、改良型藥物新劑型研發及一致性評價服務。康川濟醫藥的核心團隊具有多年的CMC研發經驗,博士、碩士佔比40%以上,能夠為新藥研發提供一流的專業技術支持。同時,康川濟醫藥擁有承接創新藥I、II期臨牀試驗樣品的交付能力,與國內多家知名製藥企業和新藥研創公司建立了廣泛合作關係。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.